Current issues in global tuberculosis control

International Journal of Infectious Diseases

Volumn 9, Issue 6, 2005, Pages 297-311

  Frothingham, Richard ^a,b   Stout, Jason E ^a   Hamilton, Carol Dukes ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

BCG vaccine; HIV infection; Latent infection; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRETROVIRUS AGENT; BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMIGRANT; LIVER TOXICITY; MULTIDRUG RESISTANCE; PREVALENCE; REVIEW; RISK ASSESSMENT; SCREENING; TUBERCULIN TEST; TUBERCULOSIS; VIRUS INFECTION;

ANTITUBERCULAR AGENTS; BCG VACCINE; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VIRUS LATENCY; WORLD HEALTH;

EID: 26944477382     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2005.04.001     Document Type: Review

References (114)

1. World Health Organization. Tuberculosis. Accessed at http://www.who.int/ mediacentre/factsheets/fs104/en/print.html on 6 November 2004.
2. J.W. Pape, S.S. Jean, J.L. Ho, A. Hafner, and W.D. Johnson Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection Lancet 342 1993 268 272
3. C.C. Whalen, J.L. Johnson, A. Okwera, D.L. Hom, R. Huebner, and P. Mugyenyi A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration N Engl J Med 337 1997 801 808
4. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society MMWR Recomm Rep 49 RR-6 2000 1 51
5. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000 MMWR Morb Mortal Wkly Rep 50 2001 289 291
6. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003 MMWR Morb Mortal Wkly Rep 52 2003 735 739
7. R.A. Garibaldi, R.E. Drusin, S.H. Ferebee, and M.B. Gregg Isoniazid-associated hepatitis. Report of an outbreak Am Rev Respir Dis 106 1972 357 365
8. D.E. Kopanoff, D.E. Snider Jr., and G.J. Caras Isoniazid-related hepatitis. A U.S. Public Health Service Cooperative Surveillance Study Am Rev Respir Dis 117 1978 991 1001
9. M.A. Steele, R.F. Burk, and R.M. DesPrez Toxic hepatotoxicity with isoniazid and rifampin: a meta-analysis Chest 99 1991 465 471
10. P.A.M. LoBue Use of isoniazid for latent tuberculosis infection in a public health clinic Am J Respir Crit Care Med 168 2003 443 447
11. F. Gordin, R.E. Chaisson, J.P. Matts, C. Miller, M. de Lourdes Garcia, and R. Hafner Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial JAMA 283 2000 1445 1450
12. K.G. Castro, J.A. Jereb, V.R. Koppaka, and D.L. Cohn Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection Chest 123 2003 967
13. L. McNeill, M. Allen, C. Estrada, and P. Cook Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis - Improved completion rates but more hepatotoxicity Chest 123 2003 102 106
14. J.E. Stout, J.J. Engemann, A.C. Cheng, E.R. Fortenberry, and C.D. Hamilton Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis Am J Respir Crit Care Med 167 2003 824 827
15. F.M. Gordin, D.L. Cohn, J.P. Matts, R.E. Chaisson, and R.J. O'Brien Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 39 2004 561 565
16. R. van Hest, H. Baars, S. Kik, P. van Gerven, M.C. Trompenaars, and N. Kalisvaart Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment Clin Infect Dis 39 2004 488 496
17. J. Saukkonen Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice Clin Infect Dis 39 2004 566 568
18. N.E. Aronson, M. Santosham, G.W. Comstock, R.S. Howard, L.H. Moulton, and E.R. Rhoades Long-term efficacy of BCG vaccine in American Indians and Alaska natives - A 60-year follow-up study JAMA 291 2004 2086 2091
19. E.A. Talbot, M.D. Perkins, S.F. Silva, and R. Frothingham Disseminated bacille Calmette-Guerin disease after vaccination: case report and review Clin Infect Dis 24 1997 1139 1146
20. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices MMWR Recomm Rep 45 RR-4 1996 1 18
21. M.P. Hawken, H.K. Meme, L.C. Elliott, J.M. Chakaya, J.S. Morris, and W.A. Githui Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial AIDS 11 1997 875 882
22. A. Mwinga, M. Hosp, P. Godfrey-Faussett, M. Quigley, P. Mwaba, and B.N. Mugala Twice weekly tuberculosis preventive therapy in HIV infection in Zambia AIDS 12 1998 2447 2457
23. J.B. Shaw, and N. Wynn-Williams Infectivity of pulmonary tuberculosis in relation to sputum status Am Rev Tuberc 69 1954 724 732
24. S. Grzybowski, G.D. Barnett, and K. Styblo Contacts of cases of active pulmonary tuberculosis Bull Int Union Tuberc 50 1975 90 106
25. United Nations Department of Economic and Social Affairs, Population Division. International migration report, 2002. Accessed at http://www.un.org/ esa/population/publications/ittmig2002/ittmig2002.htm on 18 June 2004.
26. Office of Immigration Statistics. Yearbook of immigration statistics, 2002. Accessed at http://uscis.gov/graphics/shared/aboutus/statistics/ Yearbook2002.pdf on 18 June 2004.
27. United States Census Bureau. The foreign-born population: 2000. Accessed at http://www.census.gov/prod/2003pubs/c2kbr-34.pdf on 18 June 2004.
28. B.D. Gushulak, and D.W. MacPherson Globalization of infectious diseases: The impact of migration Clin Infect Dis 38 2004 1742 1748
29. World Health Organization. WHO Report 2003: Global Tuberculosis Control. Accessed at http://www.who.int/gtb/publications/globrep03/download.html on 18 June 2004.
30. Trends in tuberculosis - United States, 1998-2003 MMWR Morb Mortal Wkly Rep 53 2004 209 214
31. E.A. Talbot, M. Moore, E. McCray, and N.J. Binkin Tuberculosis among foreign-born persons in the United States, 1993-1998 JAMA 284 2000 2894 2900
32. R. Long, K. Sutherland, D. Kunimoto, R. Cowie, and J. Manfreda The epidemiology of tuberculosis among foreign-born persons in Alberta, Canada, 1989-1998: identification of high risk groups Int J Tuberc Lung Dis 6 2002 615 621
33. L.R. Codecasa, A.D. Porretta, A. Gori, F. Franzetti, E.A. Degli, and A. Lizioli Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996 Int J Tuberc Lung Dis 3 1999 589 595
34. Moore DAJ, L. Lightstone, B. Javid, and J.S. Friedland High rates of tuberculosis in end-stage renal failure: The impact of international migration Emerg Infect Dis 8 2002 77 78
35. R. Lumb, I. Bastian, D. Dawson, C. Gilpin, F. Haverkort, and G. James Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2001 Commun Dis Intell 27 2003 173 180
36. R.E. Watkins, and A.J. Plant Predicting tuberculosis among migrant groups Epidemiol Infect 129 2002 623 628
37. W.L. Wobeser, L. Yuan, M. Naus, P. Corey, J. Edelson, and N. Heywood Expanding the epidemiologic profile: risk factors for active tuberculosis in people immigrating to Ontario CMAJ 163 2000 823 828
38. R.E. Watkins, A.J. Plant, and B.D. Gushulak Tuberculosis rates among migrants in Australia and Canada Int J Tuberc Lung Dis 6 2002 641 644
39. C. Scolari, I. El Hamad, A. Matteelli, L. Signorini, E. Bombana, and R. Moioli Incidence of tuberculosis in a community of Senegalese immigrants in Northern Italy Int J Tuberc Lung Dis 3 1999 18 22
40. T. Lillebaek, A.B. Andersen, A. Dirksen, E. Smith, L.T. Skovgaard, and A. Kok-Jensen Persistent high incidence of tuberculosis in immigrants in a low-incidence country Emerg Infect Dis 8 2002 679 684
41. R.L. Cowie, and J.W. Sharpe Tuberculosis among immigrants: interval from arrival in Canada to diagnosis. A 5-year study in southern Alberta CMAJ 158 1998 599 602
42. P.L. Zuber, M.T. McKenna, N.J. Binkin, I.M. Onorato, and K.G. Castro Long-term risk of tuberculosis among foreign-born persons in the United States JAMA 278 1997 304 307
43. J.H. Li, C.R. Driver, S.S. Munsiff, R. Yip, and P.I. Fujiwara Differential decline in tuberculosis incidence among US- and non-US-born persons in New York City Int J Tuberc Lung Dis 7 2003 451 457
44. R. Kempainen, K. Nelson, D.N. Williams, and L. Hedemark Mycobacterium tuberculosis disease in Somali immigrants in Minnesota Chest 119 2001 176 180
45. Increase in African immigrants and refugees with tuberculosis - Seattle-King County, Washington, 1998-2001 MMWR Morb Mortal Wkly Rep 51 2002 882 883
46. H. Huerga, R. Lopez-Velez, E. Navas, and E. Gomez-Mampaso Clinicoepidemiological features of immigrants with tuberculosis living in Madrid, Spain Eur J Clin Microbiol Infect Dis 19 2000 236 237
47. H.L. Rieder, D.E. Snider Jr., and G.M. Cauthen Extrapulmonary tuberculosis in the United States Am Rev Respir Dis 141 1990 347 351
48. C.M. Nolan, M.L. Aitken, A.M. Elarth, K.M. Anderson, and W.T. Miller Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees Am Rev Respir Dis 133 1986 431 436
49. D.H. Truong, L.L. Hedemark, J.K. Mickman, L.B. Mosher, S.E. Dietrich, and P.W. Lowry Tuberculosis among Tibetan immigrants from India and Nepal in Minnesota, 1992-1995 JAMA 277 1997 735 738
50. H.M. El Sahly, G.J. Adams, H. Soini, L. Teeter, J.M. Musser, and E.A. Graviss Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas J Infect Dis 183 2001 461 468
51. D.L. Cohn, F. Bustreo, and M.C. Raviglione Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease Clin Infect Dis 24 1997 S121 S130
52. P.F. Barnes, and M.D. Cave Molecular epidemiology of tuberculosis N Engl J Med 349 2003 1149 1156
53. T. Lillebaek, A.B. Andersen, J. Bauer, A. Dirksen, S. Glismann, and P. de Haas Risk of Mycobacterium tuberculosis transmission in a low-incidence country due to immigration from high-incidence areas J Clin Microbiol 39 2001 855 861
54. E. Hernandez-Garduno, D. Kunimoto, L. Wang, M. Rodrigues, R.K. Elwood, and W. Black Predictors of clustering of tuberculosis in Greater Vancouver: a molecular epidemiologic study CMAJ 167 2002 349 352
55. S. Kulaga, M. Behr, K. Musana, J. Brinkman, D. Menzies, and P. Brassard Molecular epidemiology of tuberculosis in Montreal CMAJ 167 2002 353 354
56. U.R. Dahle, P. Sandven, E. Heldal, and D.A. Caugant Continued low rates of transmission of Mycobacterium tuberculosis in Norway J Clin Microbiol 41 2003 2968 2973
57. M.W. Borgdorff, M.A. Behr, N.J. Nagelkerke, P.C. Hopewell, and P.M. Small Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity Int J Tuberc Lung Dis 4 2000 287 294
58. M.C. Gutierrez, V. Vincent, D. Aubert, J. Bizet, O. Gaillot, and L. Lebrun Molecular fingerprinting of Mycobacterium tuberculosis and risk factors for tuberculosis transmission in Paris, France, and surrounding area J Clin Microbiol 36 1998 486 492
59. D.P. Chin, K. DeRiemer, P.M. Small, A.P. de Leon, R. Steinhart, and G.F. Schecter Differences in contributing factors to tuberculosis incidence in U.S. - born and foreign-born persons Am J Respir Crit Care Med 158 1998 1797 1803
60. E. Geng, B. Kreiswirth, C. Driver, J. Li, J. Burzynski, and P. DellaLatta Changes in the transmission of tuberculosis in New York City from 1990 to 1999 N Engl J Med 346 2002 1453 1458
61. A. Matteelli, A. Gori, G. Pinsi, I. El Hamad, E. Bombana, and F. Mastaglia Clustering of tuberculosis among Senegalese immigrants in Italy Int J Tuberc Lung Dis 7 2003 967 972
62. A. Bandera, A. Gori, L. Catozzi, E.A. Degli, G. Marchetti, and C. Molteni Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis J Clin Microbiol 39 2001 2213 2218
63. A.L. Davidow, B.T. Mangura, E.C. Napolitano, and L.B. Reichman Rethinking the socioeconomics and geography of tuberculosis among foreign-born residents of New Jersey, 1994-1999 Am J Public Health 93 2003 1007 1012
64. V. Rosenfeldt, A. Paerregaard, K. Fuursted, V. Braendholt, and N.H. Valerius Childhood tuberculosis in a Scandinavian metropolitan area 1984-93 Scand J Infect Dis 30 1998 53 57
65. C.P. Chaulk, L. Khoo, D.L. Matuszak, and E. Israel Case characteristics and trends in pediatric tuberculosis, Maryland, 1986-1993 Public Health Rep 112 1997 146 152
66. X.T. Ussery, S.E. Valway, M. Mckenna, G.M. Cauthen, E. McCray, and I.M. Onorato Epidemiology of tuberculosis among children in the United States: 1985 to 1994 Pediatr Infect Dis J 15 1996 697 704
67. Recommendations for prevention and control of tuberculosis among foreign-born persons. Report of the Working Group on Tuberculosis among Foreign-Born Persons. Centers for Disease Control and Prevention MMWR Recomm Rep 47 RR-16 1998 1 29
68. D. Menzies Screening immigrants to Canada for tuberculosis: chest radiography or tuberculin skin testing? CMAJ 169 2003 1035 1036
69. S. Verver, D. van Soolingen, and M.W. Borgdorff Effect of screening of immigrants on tuberculosis transmission Int J Tuberc Lung Dis 6 2002 121 129
70. S.C. Pang, R.H. Harrison, J. Brearley, V. Jegathesan, and A.S. Clayton Tuberculosis surveillance in immigrants through health undertakings in Western Australia Int J Tuberc Lung Dis 4 2000 232 236
71. L.E. Thorpe, K. Laserson, S. Cookson, W. Mills, K. Field, and V.R. Koppaka Infectious tuberculosis among newly arrived refugees in the United States N Engl J Med 350 2004 2105 2106
72. S. Sciortino, J. Mohle-Boetani, S.E. Royce, D. Will, and D.P. Chin B notifications and the detection of tuberculosis among foreign-born recent arrivals in California Int J Tuberc Lung Dis 3 1999 778 785
73. J.L. van Burg, S. Verver, and M.W. Borgdorff The epidemiology of tuberculosis among asylum seekers in The Netherlands: implications for screening Int J Tuberc Lung Dis 7 2003 139 144
74. R.M. Granich, P.L. Zuber, M. McMillan, J.D. Cobb, J. Burr, and E.D. Sfakianaki Tuberculosis among foreign-born residents of southern Florida, 1995 Public Health Rep 113 1998 552 556
75. K. Schwartzman, and D. Menzies Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis Am J Respir Crit Care Med 161 2000 780 789
76. K. Dasgupta, K. Schwartzman, R. Marchand, T.N. Tennenbaum, P. Brassard, and D. Menzies Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations Am J Respir Crit Care Med 162 2000 2079 2086
77. N.R. Kandula, M.S. Dworkin, M.R. Carroll, and D.S. Lauderdale Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy Am J Prev Med 26 2004 163 166
78. K. DeRiemer, D.P. Chin, G.F. Schecter, and A.L. Reingold Tuberculosis among immigrants and refugees Arch Intern Med 158 1998 753 760
79. S.E. Weis, P.K. Moonan, J.M. Pogoda, L. Turk, B. King, and S. Freeman-Thompson Tuberculosis in the foreign-born population of Tarrant county, Texas by immigration status Am J Respir Crit Care Med 164 2001 953 957
80. A. Matteelli, C. Casalini, M.C. Raviglione, I. El Hamad, C. Scolari, and E. Bombana Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy Am J Respir Crit Care Med 162 2000 1653 1655
81. I. El Hamad, C. Casalini, A. Matteelli, S. Casari, M. Bugiani, and M. Caputo Screening for tuberculosis and latent tuberculosis infection among undocumented immigrants at an unspecialised health service unit Int J Tuberc Lung Dis 5 2001 712 716
82. G.H. Bothamley, J.P. Rowan, C.J. Griffiths, M. Beeks, M. McDonald, and E. Beasley Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless Thorax 57 2002 45 49
83. D.L. Saunders, D.M. Olive, S.B. Wallace, D. Lacy, R. Leyba, and N.E. Kendig Tuberculosis screening in the federal prison system: an opportunity to treat and prevent tuberculosis in foreign-born populations Public Health Rep 116 2001 210 218
84. D. Menzies Controlling tuberculosis among foreign born within industrialized countries: expensive band-aids Am J Respir Crit Care Med 164 2001 914 915
85. S. Asch, B. Leake, and L. Gelberg Does fear of immigration authorities deter tuberculosis patients from seeking care? West J Med 161 1994 373 376
86. R.E. Upshur, L. Deadman, P. Howorth, and L. Shortt The effect of tuberculosis and tuberculosis contact tracing on school function: an exploratory focus group study Can J Public Health 90 1999 389 391
87. T. Kerr, K. Kaplan, P. Suwannawong, R. Jurgens, and E. Wood The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes Lancet 364 2004 11 12
88. R. Walgate Global Fund for AIDS, TB and malaria opens shop Bull World Health Organ 80 2002 259
89. B.J. van Wolleswinkel, N.J. Nagelkerke, J.F. Broekmans, and M.W. Borgdorff The impact of immigration on the elimination of tuberculosis in The Netherlands: a model based approach Int J Tuberc Lung Dis 6 2002 130 136
90. C. Dye, S. Scheele, P. Dolin, V. Pathania, and M.C. Raviglione Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project JAMA 282 1999 677 686
91. K.A. Sepkowitz, J. Raffalli, L. Riley, T.E. Kiehn, and D. Armstrong Tuberculosis in the AIDS era Clin Microbiol Rev 8 1995 180 199
92. J.H. Perriens, R.L. Colebunders, C. Karahunga, J.C. Willame, J. Jeugmans, and M. Kaboto Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire Am Rev Respir Dis 144 1991 750 755
93. E.L. Korenromp, F. Scano, B.G. Williams, C. Dye, and P. Nunn Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review Clin Infect Dis 37 2003 101 112
94. C. Whalen, C.R. Horsburgh Jr., D. Hom, C. Lahart, M. Simberkoff, and J. Ellner Accelerated course of human immunodeficiency virus infection after tuberculosis Am J Respir Crit Care Med 151 1995 129 135
95. K.A. Wendel, K.S. Alwood, R. Gachuhi, R.E. Chaisson, W.R. Bishai, and T.R. Sterling Paradoxical worsening of tuberculosis in HIV-infected persons Chest 120 2001 193 197
96. M. Narita, D. Ashkin, E.S. Hollender, and A.E. Pitchenik Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS Am J Respir Crit Care Med 158 1998 157 161
97. K.K. Oursler, R.D. Moore, W.R. Bishai, S.M. Harrington, D.S. Pope, and R.E. Chaisson Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors Clin Infect Dis 34 2002 752 759
98. A.M. Elliott, B. Halwiindi, R.J. Hayes, N. Luo, A.G. Mwinga, and G. Tembo The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia Trans R Soc Trop Med Hyg 89 1995 78 82
99. R.E. Chaisson, G.F. Schecter, C.P. Theuer, G.W. Rutherford, D.F. Echenberg, and P.C. Hopewell Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival Am Rev Respir Dis 136 1987 570 574
100. A. Vernon, W. Burman, D. Benator, A. Khan, L. Bozeman for the Tuberculosis Trials Consortium Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid Lancet 353 1999 1843 1847
101. F. March, X. Garriga, P. Rodriguez, C. Moreno, M. Garrigo, and P. Coll Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis Clin Infect Dis 25 1997 1044 1047
102. B.R. Edlin, J.I. Tokars, M.H. Grieco, J.T. Crawford, J. Williams, and E.M. Sordillo An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome N Engl J Med 326 1992 1514 1521
103. N.J. Hargreaves, O. Kadzakumanja, Whitty CJM, F.M. Salaniponi, A.D. Harries, and S.B. Squire Smear negative pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence Int J Tuberc Lung Dis 5 2001 847 854
104. S. Woldehanna, and J. Volmink Treatment of latent tuberculosis infection in HIV infected persons Cochrane Database Syst Rev 2 2004 1 67
105. N.A. Halsey, J.S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, and L.H. Moulton Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection Lancet 351 1998 786 792
106. D.W. Fitzgerald, M. Desvarieux, P. Severe, P. Joseph, W.D. Johnson Jr., and J.W. Pape Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial Lancet 356 2000 1470 1474
107. G.J. Churchyard, K. Fielding, S. Charalambous, J.H. Day, E.L. Corbett, and R.J. Hayes Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 17 2003 2063 2070
108. M. Badri, D. Wilson, and R. Wood Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study Lancet 359 2002 2059 2064
109. J.L. Jones, D.L. Hanson, M.S. Dworkin, and K.M. DeCock Adult/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy Int J Tuberc Lung Dis 4 2000 1026 1031
110. C.R. Horsburgh Jr., J. Gettings, L.N. Alexander, and J.L. Lennox Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000 Clin Infect Dis 33 2001 1938 1943
111. B.G. Williams, and C. Dye Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS Science 301 2003 1535 1537
112. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis Bull World Health Organ 60 1982 555 564
113. F.M. Gordin, J.P. Matts, C. Miller, L.S. Brown, R. Hafner, and S.L. John A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS N Engl J Med 337 1997 315 320
114. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention MMWR Recomm Rep 47 RR-20 1998 1 58